GYRE THERAPEUTICS INC (GYRE) — insider trading
Health Care · NASDAQ
GYRE THERAPEUTICS INC (GYRE) has 70 reported SEC Form 4 insider transactions in our data, including 18 open-market sales among the most recent 70 (latest 2026-08-03).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-03 | Kirkby Maxwell | Director | Grant / award / vesting (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-08-03 | Weston Claire | Director | Grant / award / vesting (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-06-18 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-18 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 3,000 | $6.35 | $19.1K | Form 4 |
| 2026-06-18 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 3,000 | $0.75 | $2.3K | Form 4 |
| 2026-06-11 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 2,800 | — | $0 | Form 4 |
| 2026-06-11 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 2,800 | $6.17 | $17.3K | Form 4 |
| 2026-06-11 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 2,800 | $0.75 | $2.1K | Form 4 |
| 2026-06-10 | Nussbaum Rodney L | Director | Grant / award / vesting (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-06-10 | Zhang Ping | Director | Grant / award / vesting (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-06-10 | Parry Renate | Director | Grant / award / vesting (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-06-10 | Weng Dan | Director | Grant / award / vesting (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-06-10 | Epstein David M. | Director | Grant / award / vesting (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-06-10 | Carmichael Gordon | Director | Grant / award / vesting (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 5,000 | $6.24 | $31.2K | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 5,000 | $0.75 | $3.8K | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 6,418 | — | $0 | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 6,418 | $6.21 | $39.9K | Form 4 |
| 2026-06-10 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 6,418 | $0.75 | $4.8K | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 3,000 | $6.15 | $18.4K | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 3,000 | $0.75 | $2.3K | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 14,500 | — | $0 | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 14,500 | $6.14 | $89.0K | Form 4 |
| 2026-06-09 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 14,500 | $0.75 | $10.9K | Form 4 |
| 2026-06-08 | Luo Ying | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 120,000 | — | $0 | Form 4 |
| 2026-06-08 | Bergmann Joshua Benjamin | Officer (GC and Corporate Secretary) | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-06-05 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 15,401 | — | $0 | Form 4 |
| 2026-06-05 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 15,401 | $6.40 | $98.6K | Form 4 |
| 2026-06-05 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 15,401 | $0.75 | $11.6K | Form 4 |
| 2026-06-04 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 19,575 | — | $0 | Form 4 |
| 2026-06-04 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 19,575 | $6.13 | $120.0K | Form 4 |
| 2026-06-04 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 19,575 | $0.75 | $14.7K | Form 4 |
| 2026-05-26 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 4,000 | — | $0 | Form 4 |
| 2026-05-26 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 4,000 | $6.10 | $24.4K | Form 4 |
| 2026-05-26 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 4,000 | $0.75 | $3.0K | Form 4 |
| 2026-05-22 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-05-22 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 3,500 | $6.08 | $21.3K | Form 4 |
| 2026-05-22 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 3,500 | $0.75 | $2.6K | Form 4 |
| 2026-05-21 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 12,820 | — | $0 | Form 4 |
| 2026-05-21 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 12,820 | $6.15 | $78.8K | Form 4 |
| 2026-05-21 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 12,820 | $0.75 | $9.6K | Form 4 |
| 2026-05-20 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 9,400 | — | $0 | Form 4 |
| 2026-05-20 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 9,400 | $6.15 | $57.8K | Form 4 |
| 2026-05-20 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 9,400 | $0.75 | $7.0K | Form 4 |
| 2026-05-19 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 9,120 | — | $0 | Form 4 |
| 2026-05-19 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 9,120 | $6.37 | $58.1K | Form 4 |
| 2026-05-19 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 9,120 | $0.75 | $6.8K | Form 4 |
| 2026-05-18 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 200 | — | $0 | Form 4 |
| 2026-05-18 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 200 | $6.62 | $1.3K | Form 4 |
| 2026-05-18 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 200 | $0.75 | $150 | Form 4 |
| 2026-05-15 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 13,100 | — | $0 | Form 4 |
| 2026-05-15 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 13,100 | $6.65 | $87.1K | Form 4 |
| 2026-05-15 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 13,100 | $0.75 | $9.8K | Form 4 |
| 2026-05-14 | Zhang Ping | Director | Disposition to the issuer (derivative) | 250,000 | — | $0 | Form 4 |
| 2026-05-14 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 15,580 | — | $0 | Form 4 |
| 2026-05-14 | Ye Weiguo | Officer (Chief Operating Officer) | Open-market sale | 15,580 | $6.91 | $107.7K | Form 4 |
| 2026-05-14 | Ye Weiguo | Officer (Chief Operating Officer) | Option exercise / conversion | 15,580 | $0.75 | $11.7K | Form 4 |
| 2026-05-06 | Luo Ying | Director, Officer (Chief Executive Officer) | Open-market sale | 10,136 | $8.04 | $81.5K | Form 4 |
| 2026-05-05 | Luo Ying | Director, Officer (Chief Executive Officer) | Open-market sale | 179 | $8.01 | $1.4K | Form 4 |
| 2026-05-04 | Eastling Thomas Wilson | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 33,271 | — | $0 | Form 4 |
| 2026-05-04 | Eastling Thomas Wilson | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 92,683 | — | $0 | Form 4 |
| 2026-05-04 | Eastling Thomas Wilson | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 95,060 | — | $0 | Form 4 |
| 2026-05-04 | Eastling Thomas Wilson | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 33,271 | — | $0 | Form 4 |
| 2026-05-04 | Eastling Thomas Wilson | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 11,882 | — | $0 | Form 4 |
| 2026-05-04 | Eastling Thomas Wilson | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 47,530 | — | $0 | Form 4 |
| 2026-05-04 | Eastling Thomas Wilson | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 95,060 | — | $0 | Form 4 |
| 2026-05-04 | GNI Group Ltd.; GNI USA, Inc. | 10% owner | Other acquisition or disposition (derivative) | 2,143,706 | — | — | Form 4 |
| 2026-05-04 | GNI Group Ltd.; GNI USA, Inc. | 10% owner | Other acquisition or disposition (derivative) | 458,120 | — | — | Form 4 |
Ask the chat about GYRE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: GYRE THERAPEUTICS INC (GYRE).
Last updated 2026-08-03 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.